Congratulations to client Scholar Rock on the announcement of positive topline results from the Phase 3 SAPPHIRE trial of apitegromab, an investigational muscle-targeted therapy for spinal muscular atrophy (SMA).
Scholar Rock announces positive topline results from the Phase 3 SAPPHIRE trial of our investigational treatment for spinal muscular atrophy (SMA). As we work to expedite next steps with regulators, we are grateful for the dedication of the patients, families and investigators who supported the trial. Read more: https://bit.ly/3XUr0nB